🇺🇸 FDA
Patent

US 8399472

Compositions and methods for inhibition of the JAK pathway

granted A61KA61K31/343A61K31/436

Quick answer

US patent 8399472 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Mar 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/343, A61K31/436, A61K31/505, A61K31/506